The differential expression of CA125 between serous and non-serous ovarian cancer histotypes suggests that additional biomarkers such as CRP, SAA, IL6 and IL8 may complement the diagnostic efficacy of CA125, particularly for non-serous histotypes. The gene discussed is CXCL8; the disease is ovarian serous adenocarcinoma.